Trial · NCT00746954
Buspirone as a Potential Treatment for Recurrent Central Apnea
NCT00746954, Phase 3, Terminated, VA Office of Research and Development; results first posted 2016-03-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Buspirone as a Potential Treatment for Recurrent Central Apnea. Trials, record NCT00746954. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00746954
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Buspirone as a Potential Treatment for Recurrent Central Apnea
- NCT number
- NCT00746954
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 8 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Central Apnea, Heart Failure
- Interventions
- Acetazolamide, Buspirone
- First posted
- 2008-09-04
- Last updated
- 2016-03-14
- Results first posted
- 2016-03-14
- Limitations and caveats
VA population turned out to have a high number of heart failure patients who had psychiatric co-morbidity or were empirically treated with antidepressants, precluding participation.~There were not enrolled enough participants.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Apnea-hypopnea Index (Number of Central and Mixed Apneas/Hour of Sleep) | Overnight polysomnogram over 3 separate nights |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Apnea-hypopnea Index (Number of Central and Mixed Apneas/Hour of Sleep) | Overnight polysomnogram over 3 separate nights | Comparisons among Drugs (not Arms) | APNEA-HYPOPNEA/HR by drug or placebo | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Apnea-hypopnea Index (Number of Central and Mixed Apneas/Hour of Sleep) | BUSPIRONE | 32.5 | Standard Deviation 5 | APNEA-HYPOPNEA/HR by drug or placebo | |
| Apnea-hypopnea Index (Number of Central and Mixed Apneas/Hour of Sleep) | ACETAZOLAMIDE | 31.2 | Standard Deviation 4.9 | APNEA-HYPOPNEA/HR by drug or placebo | |
| Apnea-hypopnea Index (Number of Central and Mixed Apneas/Hour of Sleep) | PLACEBO | 35.7 | Standard Deviation 8 | APNEA-HYPOPNEA/HR by drug or placebo |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1 Control to ACET to BUS | 3 | |
| Overall Study | STARTED | Arm 2 Acet to Placebo to Bus | 3 | |
| Overall Study | STARTED | Arm 3 BUS to ACET to PLA | 2 | |
| Overall Study | COMPLETED | Arm 1 Control to ACET to BUS | 3 | |
| Overall Study | COMPLETED | Arm 2 Acet to Placebo to Bus | 3 | |
| Overall Study | COMPLETED | Arm 3 BUS to ACET to PLA | 2 | |
| Overall Study | NOT COMPLETED | Arm 1 Control to ACET to BUS | 0 | |
| Overall Study | NOT COMPLETED | Arm 2 Acet to Placebo to Bus | 0 | |
| Overall Study | NOT COMPLETED | Arm 3 BUS to ACET to PLA | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 | ||
| Total, other adverse events | Arm 1 | 0 | 8 |
| Total, serious adverse events | Arm 1 | 0 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00746954
GET https://conductscience.org/api/trials/v1/NCT00746954/registered